Page 21234..1020..»

Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer

By Dr. Matthew Watson

CORAL GABLES, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced the appointment of Dr. Preethi Sundaram as Chief Product Development Officer. This position will report to the Chief Executive Officer.

View post:
Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer

To Read More: Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer
categoriaGlobal News Feed commentoComments Off on Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer | dataJuly 7th, 2021
Read All

Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777

By Dr. Matthew Watson

LEXINGTON, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the closing of its global exclusive license with Bristol Myers Squibb for Agenus’ proprietary bispecific antibody program, AGEN1777, and the U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for this therapy. AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity.

Follow this link:
Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777

To Read More: Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777
categoriaGlobal News Feed commentoComments Off on Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777 | dataJuly 7th, 2021
Read All

Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China

By Dr. Matthew Watson

NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that SciClone Pharmaceuticals (Holdings) Limited (“SciClone Pharmaceuticals”) has submitted the Biologics License Application (“BLA”) for DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma to the National Medical Products Administration (“NMPA”) of China.

Read the original here:
Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China

To Read More: Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China
categoriaGlobal News Feed commentoComments Off on Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China | dataJuly 7th, 2021
Read All

Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

By Dr. Matthew Watson

REHOVOT, Israel & WILMINGTON, Del., July 06, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021 at 9:00 am ET.

Read the original:
Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

To Read More: Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference | dataJuly 7th, 2021
Read All

Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology

By Dr. Matthew Watson

Hamilton, Bermuda, July 6, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the selection of mutant KRAS-driven colorectal cancer as the first therapeutic indication for its OligoPhore™ oligonucleotide delivery platform. The Company intends to develop the treatment under project code AM-401 with submission of an IND targeted for the end of 2022.

Read the original here:
Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology

To Read More: Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology
categoriaGlobal News Feed commentoComments Off on Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology | dataJuly 7th, 2021
Read All

Amazon Brand Registry Approves the Application for the Company’s Flagship Brand: Tauri-Gum

By Dr. Matthew Watson

NEW YORK, NY, July 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York-based diversified Life Sciences Company, today announced that its Brand Registry Application for its flagship Tauri-Gum™ brand has been approved by Amazon Inc. (“Amazon”).  Amazon Brand Registry helps the Company protect its registered Trademarks and create a trusted experience for customers. Additionally, Amazon provides a suite of tools that enable rich text images on the Amazon detail page – which helps a business drive customer conversion and increased traffic & sales.

More:
Amazon Brand Registry Approves the Application for the Company’s Flagship Brand: Tauri-Gum

To Read More: Amazon Brand Registry Approves the Application for the Company’s Flagship Brand: Tauri-Gum
categoriaGlobal News Feed commentoComments Off on Amazon Brand Registry Approves the Application for the Company’s Flagship Brand: Tauri-Gum | dataJuly 7th, 2021
Read All

Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations

By Dr. Matthew Watson

Saint-Herblain (France), July 6, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced today it has appointed Vincent Dequenne as Senior Vice President Operations and Joshua Drumm as Vice President Investor Relations.

Read the original post:
Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations

To Read More: Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations
categoriaGlobal News Feed commentoComments Off on Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations | dataJuly 7th, 2021
Read All

CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors

By Dr. Matthew Watson

DURHAM, N.C., July 06, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class yet more affordable cellular immunotherapies, today announced the appointments of Michael Fekete and Greg Tibbitts, to the Company’s board of directors. Mr. Fekete and Mr. Tibbitts bring with them a wealth of financial, capital markets and strategic expertise, and prior board level experience.

Go here to read the rest:
CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors

To Read More: CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors
categoriaGlobal News Feed commentoComments Off on CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors | dataJuly 7th, 2021
Read All

Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2021

By Dr. Matthew Watson

More here:
Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2021

To Read More: Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2021
categoriaGlobal News Feed commentoComments Off on Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2021 | dataJuly 7th, 2021
Read All

Integrity Implants and Fusion Robotics Merge to Form Accelus

By Dr. Matthew Watson

Accelus to Offer Procedure-Enabling Technology with the Goal of Making Minimally Invasive Surgery (MIS) the Standard of Care in Spine Accelus to Offer Procedure-Enabling Technology with the Goal of Making Minimally Invasive Surgery (MIS) the Standard of Care in Spine

See the original post here:
Integrity Implants and Fusion Robotics Merge to Form Accelus

To Read More: Integrity Implants and Fusion Robotics Merge to Form Accelus
categoriaGlobal News Feed commentoComments Off on Integrity Implants and Fusion Robotics Merge to Form Accelus | dataJuly 7th, 2021
Read All

AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET

By Dr. Matthew Watson

OCALA, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it will host an investor update webcast at 11:00 a.m. Eastern Time on Wednesday, July 14, 2021, to discuss recent accomplishments and upcoming milestones. Investors and other interested parties are invited to submit questions to management prior to the call's start via email to aim@crescendo-ir.com.

See the rest here:
AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET

To Read More: AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET
categoriaGlobal News Feed commentoComments Off on AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET | dataJuly 7th, 2021
Read All

Capital Increase in Genmab as a Result of Employee Warrant Exercise

By Dr. Matthew Watson

Company Announcement

Read the original post:
Capital Increase in Genmab as a Result of Employee Warrant Exercise

To Read More: Capital Increase in Genmab as a Result of Employee Warrant Exercise
categoriaGlobal News Feed commentoComments Off on Capital Increase in Genmab as a Result of Employee Warrant Exercise | dataJuly 7th, 2021
Read All

FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients

By Dr. Matthew Watson

SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that the company has received FDA clearance to proceed with a Phase 2 clinical study of RTX for treating moderate-to-severe osteoarthritis of the knee pain (OAK).

Continued here:
FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients

To Read More: FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients
categoriaGlobal News Feed commentoComments Off on FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients | dataJuly 7th, 2021
Read All

Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel…

By Dr. Matthew Watson

SANTA MONICA, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive top-line results from its confirmatory pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, for opioid overdose.

See more here:
Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel...

To Read More: Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel…
categoriaGlobal News Feed commentoComments Off on Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel… | dataJuly 7th, 2021
Read All

Auxly Strengthens Financial Position With the Implementation of Amendments to Imperial Brands $123 Million Convertible Debenture and Sale of Curative…

By Dr. Matthew Watson

TORONTO, July 06, 2021 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX - XLY) (OTCQX: CBWTF) ("Auxly" or the "Company") a leading consumer packaged goods company in the cannabis products market, is pleased to announce the implementation of amendments to certain provisions of its previously issued $123 million debenture (the “Debenture”) and investor rights agreement (the “Investor Rights Agreement”) dated September 25, 2019 (collectively, the “Amendments”) with its strategic partner, Imperial Brands PLC (“Imperial Brands”), pursuant to the terms of the previously announced amending agreement dated April 19, 2021.

View post:
Auxly Strengthens Financial Position With the Implementation of Amendments to Imperial Brands $123 Million Convertible Debenture and Sale of Curative...

To Read More: Auxly Strengthens Financial Position With the Implementation of Amendments to Imperial Brands $123 Million Convertible Debenture and Sale of Curative…
categoriaGlobal News Feed commentoComments Off on Auxly Strengthens Financial Position With the Implementation of Amendments to Imperial Brands $123 Million Convertible Debenture and Sale of Curative… | dataJuly 7th, 2021
Read All

NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors

By Dr. Matthew Watson

BELTSVILLE, Md., July 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1/2 clinical trial for NC762, a humanized B7-H4 monoclonal antibody.

Link:
NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors

To Read More: NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors
categoriaGlobal News Feed commentoComments Off on NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors | dataJuly 7th, 2021
Read All

Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis

By Dr. Matthew Watson

Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021 Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021

View original post here:
Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis

To Read More: Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis
categoriaGlobal News Feed commentoComments Off on Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis | dataJuly 7th, 2021
Read All

Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles

By Dr. Matthew Watson

– Dr. Sorensen to become CEO of a start-up hemostasis and thrombosis company – – Dr. Sorensen to become CEO of a start-up hemostasis and thrombosis company –

See the rest here:
Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles

To Read More: Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles
categoriaGlobal News Feed commentoComments Off on Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles | dataJuly 7th, 2021
Read All

XBiotech Announces Dividend to Holders of Common Stock

By Dr. Matthew Watson

AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.’s (NASDAQ: XBIT) (“XBiotech”) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common stock. This one-time, special dividend will be payable on July 23, 2021 to stockholders of record at the close of business on July 16, 2021.

Originally posted here:
XBiotech Announces Dividend to Holders of Common Stock

To Read More: XBiotech Announces Dividend to Holders of Common Stock
categoriaGlobal News Feed commentoComments Off on XBiotech Announces Dividend to Holders of Common Stock | dataJuly 7th, 2021
Read All

Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021

By Dr. Matthew Watson

Geneva, Switzerland, July 7, 2021 - Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Chief Executive Officer, Tim Dyer, will present at Access to Giving Virtual Conference at 9 AM ET on July 14, 2021. Mr. Dyer will give a corporate update, including an overview of recent advances in Addex’s clinical trial program. The conference is free to all registrants.

The rest is here:
Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021

To Read More: Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021
categoriaGlobal News Feed commentoComments Off on Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021 | dataJuly 7th, 2021
Read All

Page 21234..1020..»